Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$113.07

0.33 (0.29%)

, ALIOF

Actelion

$153.55

-3.24 (-2.07%)

05:45
11/25/16
11/25
05:45
11/25/16
05:45

Johnson & Johnson in early merger talks with Actelion, Bloomberg says

Johnson & Johnson (JNJ) has approached Actelion (ALIOF) about a possible takeover of the $17B Swiss drugmaker, Bloomberg reports, citing people familiar with the matter. Deliberations are still at a preliminary stage following J&J's initial offer, the people said, asking not to be identified because the talks are private. Actelion is working with an adviser to explore options, and any discussions may not lead to a transaction, the people added. Reference Link

JNJ

Johnson & Johnson

$113.07

0.33 (0.29%)

ALIOF

Actelion

$153.55

-3.24 (-2.07%)

JNJ Johnson & Johnson
$113.07

0.33 (0.29%)

10/18/16
UBSW
10/18/16
NO CHANGE
Target $137
UBSW
Buy
Johnson & Johnson robust pipeline underappreciated, says UBS
UBS analyst Matt Miksic said the Johnson & Johnson pipeline remains robust and is underappreciated. The analyst said the recent launch of biosimilars removes uncertainty and should be positive for the stock. He also expects the additional deployment of the company's capital - to expand its pipeline through in-licensing, partnerships or mid-sized acquisitions - to be incremental to his Buy thesis. Miksic has a $137 price target on Johnson & Johnson shares.
10/19/16
LEER
10/19/16
NO CHANGE
Target $140
LEER
Outperform
Johnson & Johnson should be bought on weakness, says Leerink
Leerink analyst Danielle Antalffy believes the recent selloff in Johnson & Johnson's shares was overdone and would recommend buying on weakness. The analyst views the company as well-equipped to manage the inevitable Remicade headwind and continues to believe Johnson & Johnson can drive improving top-line growth in 2017. She reiterates an Outperform rating and $140 price target on the shares.
10/19/16
UBSW
10/19/16
NO CHANGE
Target $144
UBSW
Buy
Johnson & Johnson has potential upside from expanding pipeline, says UBS
UBS analyst Matt Miksic noted Johnson & Johnson delivered a solid quarter and said he believes there is upside to his Buy thesis. The analyst cited the company's expanding pipeline, capital allocation strategy, and contracting across its broad portfolio and patient assistance programs is expected to help mitigate pressure from biosimilar competition. Miksic reiterated his Buy rating and raised his price target to $144 from $137 on Johnson & Johnson shares.
11/09/16
RBCM
11/09/16
NO CHANGE
RBCM
Johnson & Johnson should be bought on recent weakness, says RBC Capital
After meeting with J&J's VP, Investor Relations, RBC Capital analyst Glenn Novarro says that the company's Q3 pharma results indicate that the growth of its major drugs can more than offset any declines in Remicade sales next year. The analyst quotes J&J as saying that it has not been using price hikes to increase its sales, and he thinks that the company's diverse business model will allow it to avoid being hurt by any regulatory pressures. He is upbeat on the company's efforts to increase its margins and notes that its medical device results have improved. Novarro keeps a $133 price target and an Outperform rating on the shares.
ALIOF Actelion
$153.55

-3.24 (-2.07%)

TODAY'S FREE FLY STORIES

LEG

Leggett & Platt

$48.15

-0.21 (-0.43%)

14:20
01/19/18
01/19
14:20
01/19/18
14:20
Options
Put buying in Leggett and Platt »

Put buying in Leggett and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:20
01/19/18
01/19
14:20
01/19/18
14:20
General news
Fedspeak will be truncated next week »

Fedspeak will be…

$NSD

NASDAQ Market Internals

14:17
01/19/18
01/19
14:17
01/19/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
01/19/18
01/19
14:16
01/19/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$179.80

2.2 (1.24%)

, AMZN

Amazon.com

$1,293.32

-1.68 (-0.13%)

14:08
01/19/18
01/19
14:08
01/19/18
14:08
Periodicals
Facebook not bidding for Thursday Night Football rights, Bloomberg reports »

Facebook (FB) has decided…

FB

Facebook

$179.80

2.2 (1.24%)

AMZN

Amazon.com

$1,293.32

-1.68 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 23

    Jan

  • 31

    Jan

  • 01

    Feb

  • 07

    Feb

  • 28

    Feb

  • 18

    Mar

HPQ

HP Inc.

$23.62

0.33 (1.42%)

14:06
01/19/18
01/19
14:06
01/19/18
14:06
Conference/Events
HP Inc. to hold a webcast »

Global Head of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 22

    Jan

RENN

Renren

$10.96

-0.16 (-1.44%)

14:05
01/19/18
01/19
14:05
01/19/18
14:05
Options
Renren call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNXP

Tonix Pharmaceuticals

$3.66

0.03 (0.83%)

14:04
01/19/18
01/19
14:04
01/19/18
14:04
Hot Stocks
Tonix: Horsepox virus showed protection vs. lethal vaccinia infection in study »

Tonix Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLK

BlackRock

$587.11

7.89 (1.36%)

, CIR

Circor

$53.40

1.12 (2.14%)

14:04
01/19/18
01/19
14:04
01/19/18
14:04
Hot Stocks
BlackRock reports 12.6% passive stake in Circor »

In a regulatory filing,…

BLK

BlackRock

$587.11

7.89 (1.36%)

CIR

Circor

$53.40

1.12 (2.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 22

    Feb

VIA

Viacom

$39.70

1.85 (4.89%)

, FOXA

21st Century Fox

$36.18

-0.93 (-2.51%)

14:04
01/19/18
01/19
14:04
01/19/18
14:04
Hot Stocks
Box Office Battle: 'Jumanji,' 'The Post' expected to hold off '12 Strong' »

Still expected to remain…

VIA

Viacom

$39.70

1.85 (4.89%)

FOXA

21st Century Fox

$36.18

-0.93 (-2.51%)

LGF.B

Lionsgate

$33.25

0.41 (1.25%)

VIAB

Viacom

$33.95

1.99 (6.23%)

CMCSA

Comcast

$41.85

0.17 (0.41%)

CMCSK

Comcast

LGF.A

Lionsgate

$35.22

0.72 (2.09%)

TWX

Time Warner

$92.90

-0.07 (-0.08%)

DIS

Disney

$110.18

-0.24 (-0.22%)

SNE

Sony

$49.80

0.63 (1.28%)

FOX

21st Century Fox

$35.73

-0.76 (-2.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

BLK

BlackRock

$586.98

7.76 (1.34%)

, BXS

BancorpSouth

$34.90

0.35 (1.01%)

14:02
01/19/18
01/19
14:02
01/19/18
14:02
Hot Stocks
BlackRock reports 10.2% passive stake in BancorpSouth »

In a regulatory filing,…

BLK

BlackRock

$586.98

7.76 (1.34%)

BXS

BancorpSouth

$34.90

0.35 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 25

    Jan

14:00
01/19/18
01/19
14:00
01/19/18
14:00
General news
Action Economics Survey results: »

Action Economics Survey…

BASFY

BASF

$29.54

0.825 (2.87%)

, BAYRY

Bayer

$31.82

0.015 (0.05%)

13:57
01/19/18
01/19
13:57
01/19/18
13:57
Periodicals
Breaking Periodicals news story on BASF, Bayer »

Capitol Forum says BASF,…

BASFY

BASF

$29.54

0.825 (2.87%)

BAYRY

Bayer

$31.82

0.015 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

  • 25

    Mar

13:55
01/19/18
01/19
13:55
01/19/18
13:55
General news
SF Fed moderate Williams said economic tailwinds »

SF Fed moderate Williams…

OCPNY

Olympus Corp

$38.27

-0.12 (-0.31%)

13:54
01/19/18
01/19
13:54
01/19/18
13:54
Hot Stocks
Judge grants new trial for Bigler Family vs. Olympus wrongful-death case »

A King County court has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$77.99

0.6 (0.78%)

13:52
01/19/18
01/19
13:52
01/19/18
13:52
Periodicals
Citi plans to have post-Brexit trading hub running by year end, Bloomberg says »

Citigroup intends to have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 24

    Jan

CANF

Can-Fite BioPharma

$1.76

0.01 (0.57%)

13:50
01/19/18
01/19
13:50
01/19/18
13:50
Conference/Events
Can-Fite BioPharma participates in lunch meeting with Philadelphia Securities »

Luncheon Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

13:50
01/19/18
01/19
13:50
01/19/18
13:50
Options
VIX slips on a relatively quiet monthly expiration »

VIX slips on a relatively…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:50
01/19/18
01/19
13:50
01/19/18
13:50
General news
Oil Action: Baker-Hughes »

Oil Action: Baker-Hughes…

KMI

Kinder Morgan

$18.97

-0.045 (-0.24%)

13:45
01/19/18
01/19
13:45
01/19/18
13:45
Options
Post earnings premium seller collects $13M in KinderMorgan »

Post earnings premium…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$91.92

1.61 (1.78%)

13:45
01/19/18
01/19
13:45
01/19/18
13:45
Options
Incyte call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

PRQR

ProQR Therapeutics

13:31
01/19/18
01/19
13:31
01/19/18
13:31
Conference/Events
ProQR Therapeutics to h old an investor event »

Investor Event will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

CMC

Commercial Metals

$24.83

-0.26 (-1.04%)

13:30
01/19/18
01/19
13:30
01/19/18
13:30
Options
Second day of call buying in Commercial Metals »

Second day of call buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLEX

Flex

$19.61

0.17 (0.87%)

13:25
01/19/18
01/19
13:25
01/19/18
13:25
Options
Flex call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

CSCO

Cisco

$41.30

0.1 (0.24%)

13:22
01/19/18
01/19
13:22
01/19/18
13:22
Periodicals
Cisco expands Spectre, Meltdown investigation to nine more products, CRN reports »

Cisco added nine more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.